Premium
The use of danazol in the management of chronic immune thrombocytopenic purpura
Author(s) -
McVerry B. A.,
Auger M.,
Bellingham A. J.
Publication year - 1985
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1985.tb04070.x
Subject(s) - danazol , thrombocytopenic purpura , medicine , immune system , platelet , refractory (planetary science) , purpura (gastropod) , immunology , endometriosis , biology , ecology , astrobiology
S ummary . Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.